PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
7.01%
Some net income increase while GNPX is negative at -0.67%. John Neff would see a short-term edge over the struggling competitor.
8.54%
Some D&A expansion while GNPX is negative at -22.07%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
100.00%
Well above GNPX's 100.00% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
48.65%
SBC growth while GNPX is negative at -50.39%. John Neff would see competitor possibly controlling share issuance more tightly.
-142.09%
Negative yoy working capital usage while GNPX is 294.87%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-124.49%
Negative yoy AP while GNPX is 245.48%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-84.29%
Both reduce yoy usage, with GNPX at -103.06%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
47.93%
Some yoy increase while GNPX is negative at -128.16%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
1.55%
Some CFO growth while GNPX is negative at -6.73%. John Neff would note a short-term liquidity lead over the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
We cut debt repayment yoy while GNPX is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
1131.77%
Lower share issuance yoy vs. GNPX's 67931890.00%, implying less dilution. David Dodd would confirm the firm still has enough capital for expansions.
No Data
No Data available this quarter, please select a different quarter.